English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18055/20253 (89%)
Visitors : 43878      Online Users : 569
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34697


    標題: Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis
    作者: Chung, Mu-Chi
    Hsu, Hui-Tsung
    Chang, Chao-Hsiang
    Hung, Peir-Haur
    Hsiao, Po-Jen
    Wu, Laing-You
    Wu, Ming-Ju
    Shieh, Jeng-Jer
    Chung, Chi-Jung
    貢獻者: Taichung Veterans General Hospital
    National Chung Hsing University
    National Chung Hsing University
    Asia University Taiwan
    China Medical University Taiwan
    China Medical University Taiwan
    China Medical University Hospital - Taiwan
    Chia-Yi Christian Hospital
    Department of Applied Life Science and Health, Chia Nan University of Pharmacy & Science
    National Chung Hsing University
    Taichung Veterans General Hospital
    China Medical University Taiwan
    China Medical University Hospital - Taiwan
    關鍵字: cardiovascular outcomes
    empagliflozin
    metaanalysis
    mortality
    cancer
    日期: 2022
    上傳時間: 2023-12-11 14:05:42 (UTC+8)
    出版者: NATURE PORTFOLIO
    摘要: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) potentially decrease all-cause and cardiovascular death, however, associations with non-cardiovascular death remain unclear. Therefore, we investigated SGLT2i associations with death and the cause of death. We used the Taiwanese National Health Institutes Research database linked to the National Register of Deaths (NRD). Incident type 2 diabetes mellitus (T2DM) patients and propensity score matched T2DM SGLT2i and Dipeptidyl peptidase 4 inhibitor (DPP4i) users were investigated. The index year was the SGLT2i or DPP4i prescription date from May 2016. Patients were followed-up until death or December 2018. Deaths verified by the NRD and grouped accordingly. Multiple Cox proportional hazards models were used. In total, 261,211 patients were included in the population; 47% of the patients were female and the average age was 62 years. The overall incidence of all-cause death was 8.67/1000 patient-years for SGLT2i and 12.41 for DPP4i users during follow-up. After adjusting for potential risk factors in the propensity score matched population, SGLT2i users were associated with lower risks of all-cause death, cardiovascular death, cancer death, and non-cancer, non-vascular death compared with DPP4i-users. For specific death causes, significantly lower death risks from heart disease, cerebrovascular disease, and accidents were associated with SGLT2i-use. SGLT2i benefits for T2DM patients were not different across subgroups. Compared with DPP4i-use, SGLT2i-use for T2DM was associated with lower disease and death risk.
    關聯: SCIENTIFIC REPORTS, v.12, n.10147
    Appears in Collections:[生活保健科技系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML143View/Open
    s41598-022-13760-7.pdf1234KbAdobe PDF75View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback